Journals / Glokom Katarakt / 2015 / Cilt: 10 - Sayı: 1

Comparison of Dorzolamide/Timolol Maleate and Brinzolamide/ Timolol Maleate Fixed Combination in Patients with Primary Open Angle Glaucoma

Primer Açık Açılı Glokom Hastalarında Dorzolamid/Timolol Maleat ve Brinzolamid/ Timolol Maleat Sabit Kombinasyonlarının Karşılaştırılması

Pages
28–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was no systemic side effect in both groups. 4 patients had irritation-redness, 3 patients had foreign body sensation-ocular pain and 1 patient had temporary visual disturbance in Group 1. 3 patients had temporary visual disturbance in Group 2.Conclusion: DT and BT were effective for lowering IOP in POAG patients and BT had less side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare dorzolamid/timolol maleat (DT) and brinzolamid-timolol maleat (BT) fixed combination on lowering intraocular pressure (IOP) and side effects in patients with Primary Open Angle Glaucoma (POAG).Materials and Methods: 80 eyes of 40 patients (18 male and 22 female) were included in this retrospective study.
📊
Key Findings & Data:Inclusion criteria was; recently diagnosed POAG, age of over 18, IOP over 21 mmHg and 1 year follow-up time. 20 patients who use DT formed Group 1 and 20 patients who use BT formed Group 2.
💡
Conclusion & Impact:There was no systemic side effect in both groups. 4 patients had irritation-redness, 3 patients had foreign body sensation-ocular pain and 1 patient had temporary visual disturbance in Group 1. 3 patients had temporary visual disturbance in Group 2.Conclusion: DT and BT were effective for lowering IOP in POAG patients and BT had less side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare dorzolamid/timolol maleat (DT) and brinzolamid-timolol maleat (BT) fixed combination on lowering intraocular pressure (IOP) and side effects in patients with Primary Open Angle Glaucoma (POAG).Materials and Methods: 80 eyes of 40 patients (18 male and 22 female) were included in this retrospective study. Inclusion criteria was; recently diagnosed POAG, age of over 18, IOP over 21 mmHg and 1 year follow-up time. 20 patients who use DT formed Group 1 and 20 patients who use BT formed Group 2. Control examinations were performed every month and follow-up time was 12 months. Anterior segment and retina exams were performed with slit-lamp biomicroscopy, IOP was measured with Goldmann applanation tonometry, perimetry performed with Octopus 900.Results: Mean IOP for Group 1 and Group 2 were 23.82±1.68 and 23.96±1.80 at first exam. After using a medical treatment, IOP's of all patients were under 18 mmHg at all monthly control exams. IOP measurements significantly reduced during follow-up compared with baseline (p<0.05). During 12-month follow-up, there was no change in visual field. There was no systemic side effect in both groups. 4 patients had irritation-redness, 3 patients had foreign body sensation-ocular pain and 1 patient had temporary visual disturbance in Group 1. 3 patients had temporary visual disturbance in Group 2.Conclusion: DT and BT were effective for lowering IOP in POAG patients and BT had less side effects.

Özet

Amaç: Primer Açık Açılı Glokom (PAAG) olgularında, dorzolamid/timolol maleat (DT) ve brinzolamid-timolol maleat (BT) sabit kombinasyonlarının, göz içi basıncını (GİB) düşürmedeki etkinliklerini ve yan etkilerini kıyaslamak. Gereç ve Yöntem: Geriye dönük çalışmaya, 40 PAAG tanılı hastanın (18 erkek ve 22 kadın) 80 gözü alındı. Çalışmaya alınma kriterleri olarak; yeni tanı almış PAAG hastası olmak, 18 yaş ve üzerinde olmak, GİB'nın 21 mmHg'dan yüksek olması ve bir yıl takip süresinin olması olarak belirlendi. DT kullanan 20 hastadan Grup 1, BT kullanan 20 hastadan Grup 2 oluşturuldu. Kontrol muayeneleri her ay yapıldı ve toplam izlem süresi 12 aydı. Yarıklı lamba biyomikroskopisiyle ön segment ve retina muayenesi, Goldmann applanasyon tonometrisiyle GİB ölçümü, Octopus 900 ile görme alanı muayenesi yapıldı.Bulgular: Grup 1 ve Grup 2 için GİB ortalamaları ilk muayenelerinde sıra ile 23.82±1.68 ve 23.96±1.80 idi. Tedavi başlandıktan sonra aylık kontrol muayenelerinde tüm hastaların GİB'ları 18 mmHg'nın altında kaldı. GİB değerleri tüm kontrollerde, tanı aldıkları ilk muayenedeki ölçüme göre anlamlı olarak düşük bulundu (p<0.05). 12 aylık takip sonrasında görme alanında değişikliğe rastlanmadı. Her iki grupta sistemik bir yan etkiye rastlanmadı. Grup 1'de 4 hastada irritasyon-kızarıklık, 3 hastada yabancı cisim hissi-oküler ağrı ve 1 hastada geçici bulanık görmeye rastlandı. Grup 2'de 3 hastada geçici görme bulanıklığına rastlandı.Sonuç: PAAG hastalarında GİB'nın düşürülmesinde DT ve BT sabit kombinasyonlarının etkili olduğu ve BT'nin daha az yan etkisinin olduğu gözlemlendi.

🔖

Cite This Article

ÖZBAŞ, M., YILMAZ, İ., AYGIT, E. D., ALKIN, Z., ÖZKAYA, A. (2015). Comparison of Dorzolamide/Timolol Maleate and Brinzolamide/ Timolol Maleate Fixed Combination in Patients with Primary Open Angle Glaucoma. Glokom Katarakt, Cilt: 10 - Sayı: 1, 28–32. https://ajindex.com/articles/204321

References (12)

  1. Honkanen RA, Baruah S, Zimmerman MB et al. Vitreous aminoasid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol 2003;121:183-88.
  2. Leske MC, Heijl A, Hussein M et al. Factors of glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2002;121:48-56. Terminology and Guidelines for Glaucoma. 3rd Edition 2008:132. Orhan M, Suyugül N, Turaçlı E ve ark. Glokom. Ankara: SFN Televiz- yon Tanıtım Tasarım Yayıncılık 2003;4-76.
  3. Weinreb RN, Araie M, Susanna R et al. Medical Treatment of Glauco- ma. The 7th Consensus Report of the World Glaucoma Association. Ed: Kugler Publications 2010.
  4. Rachmiel R, Trope GE, Chipman ML et al. Laser trabeculoplasty trends with the introduction of new medical treatments and selective laser trabeculoplasty. J Glaucoma. 2006;15:306-9.
  5. Allingham R, Damji KF, Freedman S et al. Management of Glaucoma. Textbook of Glaucoma Sixth Edition 2011;389-438. Öge İ. Glokomun medikal tedavisindeki yenilikler. MN Oftalmol. 2010;17:29-35.
  6. Singh K, Shrivastava A. Early aggressive intraocular pressure lowe- ring, target intraocular pressure, and a novel concept for glaucoma care. Surv Ophthalmol 2008;53:33-8.
  7. Çankaya AB, Elgin U, Şimşek T ve ark. Primer açık açılı glokom olgu- larında latanoprost- timolol maleat sabit kombinasyonunun etkinliği- nin retrospektif olarak değerlendirilmesi. Glo-Kat 2008;3:77-81.
  8. Esen D, Ülke M, Buttanrı İB ve ark. Primer açık açılı glokomlu hasta- larda latanoprost %0.005 ve timolol maleat %0.5 sabit kombinasyonu- nun etkinliği. Glo-Kat 2010;5:34-7. Sugrue MF. Pharmacological and ocular hypotensive properties of to- pical carbonic anhydrase inhibitors. Progress in Retinal and Eye Rese- arch 2000;19:87-112
  9. Grehn F, Hollo G, Lachtar Y et al. General principles of glaucoma tre- atment. In Traverso CE: Terminology and guidelines for glaucoma, 2 nd edition 2004;3:3-3.
  10. Heijl A, Leske C, Bengtsson B et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79. The AGIS Investigators: The advanced glaucoma intervention study (AGIS) 7: The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40.
  11. Cioffi GA, Durcan FJ, Girkin CA et al. Glaucoma. In Skuta GL, Cantor LB, Weiss JS: Basic and Clinical Science Course AAO 2008;10:167-86.
  12. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular